CG Oncology (CGON) Prices Upsized 20M Share IPO at $19/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- S&P 500, Nasdaq futures slip after tech rally; Warsh's speech awaited
- Oil holds steady, on track for weekly fall on US-Iran talks stalemate
- Dollar heads for weekly gain as Warsh remarks awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
CG Oncology Announces Pricing of Upsized Initial Public Offering
January 24, 2024 7:10 PM ESTIRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its upsized initial public offering of 20,000,000 shares of its common stock at an initial public offering price of $19.00 per share. All of the shares are being offered by CG Oncology. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $380.0 million. CG Oncologys common... More
